Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study
ILD risk is elevated in EGFR-TKI-treated NSCLC patients, particularly with older age, comorbidities, and lansoprazole use. Clinicians should consider these factors to reduce ILD incidence.
Authors
- Rong Zhao (ORCID: https://orcid.org/0000-0002-3235-0123)
- Xiaoqin Li (ORCID: https://orcid.org/0000-0003-3762-9817)
- Miao Xu (ORCID: https://orcid.org/0000-0003-0639-711X)
- Yuan Liu (ORCID: https://orcid.org/0009-0001-9551-2900)
Institutions
- Jiangsu University (CN)
- Shandong Institute of Food and Drug Inspection (CN)
- Affiliated Hospital of Jiangsu University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3389/fphar.2025.1652750
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 4.56